You are here: Industry Insights > BMS

News List

PsiOxus Achieves $15M BMS Milestone contractpharma
December 13, 2017
PsiOxus Therapeutics’ Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved, triggering a $15 million milestone payment from development partner, Bristol-Myers Squibb.
BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer pharmafile
October 16, 2017
On initial review of the drug, NICE found that evidence on Opdivo’s efficacy in head and neck cancer proved inconclusive and could not approve it for use on the NHS.
BMS’ Opdivo to finally be made available to lung cancer patients in the UK pharmafile
September 21, 2017
It is two and a half years since patients with lung cancer in the US were able to receive Bristol-Myers Squibb’s Opdivo for treatment, the UK has finally caught up after NICE's approval of the drug.
Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer pharmatimes
August 17, 2017
A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.
BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer pharmafile
August 17, 2017
Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo and Yervoy failed to show any statistically significant benefits in progression-free survival versus Pfizer’s Sutent in the ...
BMS and Clovis Oncology Enter Clinical Collaboration contractpharma
August 04, 2017
Will evaluate combination of Opdivo and Rubraca in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types
BMS and Clovis Oncology announce a broad clinical collaboration to evaluate combination of Opdivo an cphi-online
August 01, 2017
Pivotal Phase III trials planned for 2017 will evaluate Rubraca + Opdivo, Rubraca as monotherapy, and Opdivo as monotherapy in first line maintenance treatment for advanced ovarian and advanced triple-negative breast cancers.
FDA Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Un drugs.com
July 26, 2017
Bristol-Myers Squibb Company (NYSE:BMY) announced that FDA has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and olde
What Makes Biogen (BIIB) and Bristol-Myers Squibb (BMS Such Attractive Takeover Targets BioSpace.com
June 28, 2017
Merger-and-acquisition activity is expected to pick up for the last half of this year. This is based largely on the loss of prominent patents in the biopharma industry, and what appears to be a build-up of cash reserves.
BMS, Novartis to test Mekinist/Opdivo combo pharmatimes
June 07, 2017
Novartis and Bristol-Myers Squibb have signed a clinical research pact to investigate the safety, tolerability, and efficacy of combining their respective drugs Mekinist and Opdivo.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page